Abstract
Background/Aim: Lack of interchangeability between prostate-specific antigen (PSA) assays could have a clinical impact. We compared PSA assays from different manufacturers and calibrations. Patients and Methods: A total of 233 men who underwent prostate biopsy (PSA: 2-10 ng/ml; Beckman Coulter Access® Hybritech® as reference) were enrolled. Total (tPSA) and free PSA (fPSA) were also measured using the Roche cobas® and the Abbott Architect® methods. Results: Roche tPSA values were ≈ 1% higher than Beckman, while Abbott values were ~5% lower. Roche had the highest diagnostic sensitivity (92%) compared to Beckman Coulter (87%) and Abbott (85%). Roche fPSA was ≈3% lower and Abbott ≈17% higher than that of Beckman. For the percentage of fPSA, Roche had the highest sensitivity (98%). Conclusion: Roche cobas® and Beckman Coulter Access® Hybritech® tPSA were almost interchangeable. While the agreement was acceptable for tPSA, this did not happen with fPSA and greater efforts for harmonization are required.
Original language | English |
---|---|
Pages (from-to) | 3431-3439 |
Number of pages | 9 |
Journal | In Vivo |
Volume | 35 |
Issue number | 6 |
DOIs | |
Publication status | Published - Dec 2021 |
Keywords
- Free PSA
- Hybritech calibration
- Method comparison
- Prostate cancer
- Total PSA
- WHO calibration